Kornimate/medical-research-clean huggingface dataset:
h-pylori infection with disease activity in systemic lupus erythematosus and rheumatoid arthritis

Conditions: Helicobacter Pylori Infection

Summary: to find the relation of helicobacter pylori with disease activity in sle and ra

h. pylori is a widespread, spiral-shaped, flagellated gram-negative bacterium usually infects the gastric mucosa.its seropositivity increases with age as it affects about eighty percent of the middle-aged adults in the developing countries and about twenty-five to fifty percent in the western populations.the relation between infection and autoimmune diseases has been previously investigated. many gram-negative bacteria as salmonella, shigella, and chlamydia were confirmed to be associated with the development of reactive arthritis.these bacteria have been found to stimulate the host immune response due to the presence of lipopolysaccharides and other antigenic molecules that can cause inflammation.it has been previously hypothesized that h. pylori can induce such immune host response through many mechanisms as the molecular mimicry and antigenic similarity, disruption of the tolerogenic immune response, and activation of the polyclonal lymphocytes leading ultimately to the imbalance between t regulatory/th17 cells in addition to the induction of autoantibody production

Eligibility criteria:
inclusion criteria: 1. patients with sle and ra who were admitted to rheumatology unit in internal medicine department, assuit university hospital will be enrolled in this study exclusion criteria: * any patient or control known to have treatment for h. pylori or taking antibiotic treatment for the previous three months 2- patients receiving biologic therapy 3-patients known to have diabetes mellitus, autoimmune thyroid disease or autoimmune hepatitis or any other autoimmune
incidence of complete posterior vitreous detachment after trabeculectomy.

Conditions: Posterior Vitreous Detachment

Summary: intraocular surgery could induce vitreous degeneration and posterior vitreous detachment (pvd). vitreomacular interface (vmi) abnormalities usually are caused by abnormal pvd, vitreoschisis and partial-thickness pvd. furthermore, the pvd could induce the peripheral break. the incidence of peripheral break and epimacular membrane (emm) after pneumatic retinopexy were 11.7% and 4-11%, respectively. although multiple intravitreal anti-vascular endothelial growth factor (anti-vegf) injections induced pvd of 5.6%, but peripheral break was reported as only 0.67%. the most common intraocular surgery is cataract surgery. from the literature review, many methods were used to detect the pvd after phacoemulsification. the former studies used indirect ophthalmoscopy and ocular ultrasound for diagnosis of pvd. the later studies used the optical coherence tomography (oct) for pvd detection. the oct device had higher effectiveness in evaluation of the posterior segment, then it can detect post-phacoemulsification pvd more and early than previous studies. ivastinovic et al demonstrated 59.2% of patients had pvd at 1 month after phacoemulsification, and increased up to 71.4% at 3 months. the incidence of rhegmatogenous retinal detachment (rrd) after phacoemulsification is gradually increased with time. the accumulative risk of rrd was increased from 0.27% at 1 year to 1.27% at 20 years after phacoemulsification.

trabeculectomy is one of the intraocular surgery. although the volume of intraocular fluid use during the trabeculectomy was much less than used during phacoemulsification, trabeculectomy also could induce the pvd and it's sequelae such as vmi abnormalities. because the baseline visual acuity of glaucoma patients who were indicated for trabeculectomy usually quite poor, so the sequelae of pvd can cause more visual loss. the incidence of pvd after trabeculectomy has never been published before and nowadays no standard guideline for retinal examination or screening after surgery. furthermore, tsukahara et al introduced wide-field oct-based pvd classification. the new oct device with higher technology will be useful in pvd detection.

Eligibility criteria:
inclusion criteria: * primary open angle glaucoma or primary angle closure glaucoma * age 18-65 years * could be taken the wide-field oct images * written informed consent exclusion criteria: * history of intraocular inflammation or infection * history of ocular trauma or head trauma * history of intraocular surgery such as intravitreal drug injection and cataract surgery * history of vitreoretinal diseases such as diabetic retinopathy, retinal vascular occlusion and age-related macular degeneration * history of laser treatment including laser capsulotomy and retinal photocoagulation * high myopia; spherical equivalence \>4 diopters * complete pvd was detected before the enrollment

Keywords: posterior vitreous detachment trabeculectomy vitreomacular interface
comparison of continuous wound catheter infusion versus continuous epidural infusion in abdominal surgery

Conditions: Upper Gastrointestinal Surgery; Post-operative Analgesia; Wound Infusion Catheter; Upper Midline Incision

Summary: comparison of efficacy in management of pain in abdominal surgery between epidural versus wound infusion catheter {catheter placed within the incision site}


Eligibility criteria:
inclusion criteria: * asa ps i-iii , undergoing upper gastrointestinal surgery involving upper midline incision exclusion criteria: * refusal to give consent. * contraindication to epidural analgesia (e.g.localized sepsis , raised icp , myelopathy , peripheral neuropathy ,inherited coagulopathy) * addiction to opioids, or alcohol, or history of any other substance abuse. * allergy to local anaesthetic drugs. * pregnancy. * inability to communicate (e.g. known psychiatric disorders)
buprenorphine for prisoners

Conditions: Heroin Addiction

Summary: this five-year study examines the effectiveness of buprenorphine treatment provided to previously-addicted inmates(n=320; 160 males, 160 females) initiated in prison and continued in the community. the study also examines the extent to which the setting of post-release buprenorphine is provided.it is expected that participants receiving in-prison buprenorphine will have superior outcomes compared to participants who did not receive in-prison buprenorphine.

participants will be randomly assigned, within gender, to one of four treatment conditions: 1) buprenorphine and counseling in prison, with referral for continued treatment at an otp upon release; 2) buprenorphine and counseling in prison, with referral for continued treatment at a chc upon release; 3) counseling only in prison, with referral for buprenorphine and counseling at a otp upon release; and 4) counseling only in prison, with referral for buprenorphine and counseling at a chc upon release. participants will be assessed at study entry and at 1, 3, 6, and 12 months following their release from prison. outcome measures include: treatment entry and retention in the community, heroin use, cocaine use, hiv infection, hiv-risk behaviors, criminal activity, and employment.

Eligibility criteria:
inclusion criteria: 1. pre-release prison inmate with 3-6 months remaining until planned release 2. history of heroin dependence(meeting dsm-iv criteria of heroin dependence at the time of incarceration and manifesting physical dependence during the year preceding incarceration 3. suitability for buprenorphine treatment as determined by medical evaluation 4. willingness to participate in the study 5. having a baltimore address and planning to live in baltimore after release from prison - exclusion criteria: 1. evidence of kidney failure 2. evidence of liver failure 3. history of psychosis 4. having a pending parole hearing 5. unadjudicated charges that could result in additional prison time or transfer to another facility -
patients without standard modifiable cardiovascular risk factors (smurf-less) and their prognosis after a st-segment-elevation myocardial infarction (stemi)

Conditions: STEMI

Summary: the purpose of this study is to asses the prognosis of stemi patients without standard modifiable risk factors of cardiovascular disease (diabetes mellitus, hyperlipidemia, hypertension and cigarette smoking) compare to patients presenting at least one of these risk factors.


Eligibility criteria:
inclusion criteria: stemi patients who had a percutaneous coronary intervention (pci) in our pci center. exclusion criteria: pain duration exceeding 24h. perioperative stemi, including stemi related to cardiac surgery.

Keywords: smurfs smurf-less standard modifiable risk factors prognosis family history
chronic inflammatory bowel diseases (ibd) and school absenteeism

Conditions: Inflammatory Bowel Diseases

Summary: study of the causes and rate of school absenteeism in children and adolescents with inflammatory bowel disease.


Eligibility criteria:
inclusion criteria: * child aged 6 to 18 years old * child with definite diagnosis of ibd for at least 6 months * follow-up by a gastroenterologist of rennes university hospital on a regular basis (at least 2 annual consultations) * non-opposition of the child and the parents exclusion criteria: * school leaving * student at the university * other serious disease outside ibd preventing normal schooling * refusal of participation
performance of 2win photoscreener with corneal reflex compared to school bus retinoscopy by aapos guidelines

Conditions: Refractive Errors; Amblyopia; Strabismus; Development Delay

Summary: pediatric eye patients receive infrared photoscreener screening and skiascopy as a part of routine examination to compare ability to detect amblyopia risk factors.

patients: pediatric eye and adult strabismus patients undergoing routine examinations in a private ophthalmology practice. interventions: infrared photoscreener / remote autorefractor such as 2 winner (2win) ("adaptica" - padova, italy) without and with infrared corneal reflex occluder. child-friendly skiascopy before and after cycloplegic refraction. outcome: amblyopia risk factors from comprehensive eye exam including refraction and strabismus. risk factors defined by american association for pediatric ophthalmology and strabismus (aapos) 2003 and 2013 guidelines. \*\*please note that 2 winner has nothing to do with actual device, but was required by the clinical trials web entry.\*\*

Eligibility criteria:
inclusion criteria: * patient undergoing eye examination exclusion criteria: * none
sexual health advocacy for guys - a text messaging-based hiv prevention program for guys who are into guys

Conditions: HIV Infections

Summary: shag is a text messaging-based hiv prevention program designed for cisgender sexual minority boys and men 13-20 years of age across the united states. investigators will test it against a control group that receives messages about healthy lifestyle.

shag is a text messaging-based hiv prevention program designed for cisgender sexual minority boys and men 13-20 years of age across the united states. investigators will test it against a control group that receives messages about healthy lifestyle. harnessing the power of technology, young people will be recruited online and largely enrolled digitally. the main outcome of interest is hiv incidence. the impact of the intervention on sti testing and pre-exposure prophylaxis (prep) will also be examined.

Eligibility criteria:
inclusion criteria: 1. have been assigned male sex at birth and currently have a cisgender identity; 2. be aged 13-22 years old; 3. have had anal sex in the past 12 months; 4. be english-speaking; 5. exclusively own a cell phone with an unlimited text messaging plan and intend to have the same cell phone number for the next 6 months; 6. have internet access to complete online surveys; 7. provide informed assent for those under 18, and consent for those 18 years of age and older, including a capacity to consent and a positive self-safety assessment; 8. willing to take an oraquick home test to confirm hiv negativity for youth who are 19-20 years of age or 18 years old and graduated high school. if they agree to do the test but do not upload a photo of their result, they will be eligible if they self-report a negative sero-status. youth 18 years old who have not graduated high school, and 13-17 years of age will be asked to take a home test. if they determine that they cannot do so safely, they will be allowed to self-report their sero-status; and 9. not currently enrolled in another hiv prevention program; or 10. know anyone already enrolled in the rct. exclusion criteria: * being hiv positive
juggerstitch post market clinical follow-up study

Conditions: Meniscus Tear, Tibial; Meniscus Lesion

Summary: this study is a post-market follow-up study. the data collected from this study will serve the purpose of confirming the safety and performance of the juggerstitch device used for meniscal repair according to the product labelling (instruction for use).

this study is a post-market follow-up study to fulfil the post-market surveillance obligations according to medical device directive and meddev 2.12/2 and the medical devices regulation (mdr 2017/745). the data collected from this study will serve the purpose of confirming the safety and performance of the juggerstitch device used for meniscal repair according to the product labelling (ifu). the objectives of the study are to calculate the overall clinical success rate and the performance, and confirm the safety of the juggerstitch meniscal repair device. the primary endpoint of this study is defined by the absence of reoperation due to meniscal tear. this will be measured against the success criteria of the absence of reoperation in 90.2% of the cases at one year.

Eligibility criteria:
inclusion criteria: * subject qualifies for meniscal repair based on the physical exam and medical history and meets the approved indications for use of the study product; * older than 18 years and skeletally mature; * willing and able to comply with the study procedures; * subject is capable of understanding the doctor's explanations, following his instructions and is able to participate in the follow-up program; * subject is able to read and understand the informed consent form (icf) and has voluntarily provided written informed consent. exclusion criteria: * meniscal tears in the avascular zone of meniscus; * meniscal tears not suitable for repair because of the degree of damage(marked irregularity and complex tearing) to the meniscus body including degenerative, radial, horizontal cleavage and flap tears; * presence of active infection; * if female, subject is pregnant; * subject is vulnerable (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant); * the subject is unwilling or unable to give consent or to comply with the follow-up program; * subject meets any contraindications of the appropriate instruction for use.
efficacy and safety study of gevokizumab to treat behcet's disease uveitis

Conditions: Behcet's Disease Uveitis

Summary: the objective of this study is to assess the efficacy and safety of gevokizumab in treating behcet's disease uveitis (bdu).


Eligibility criteria:
inclusion criteria: * have characteristics of behcet's disease consistent with international criteria for behcet's disease * have a documented history of active uveitis with or without retinal vasculitis within the past 12 months * best corrected visual acuity (bcva) \>= 20 etdrs letters in both eyes at baseline * effective contraceptive measures exclusion criteria: * infectious uveitis and masquerade syndromes * end stage ocular disease * history of allergic or anaphylactic reactions to monoclonal antibodies * active tuberculosis disease * history of recurrent infection or predisposition to infection; active ocular infection * pregnant or nursing women other protocol-defined inclusion/exclusion criteria may apply

Keywords: uveitis behcet's disease uveitis behcet's disease
a continuation trial for subjects with lupus who completed protocol hgs1006-c1056 in the united states

Conditions: Systemic Lupus Erythematosus

Summary: this is a continuation study to provide continuing treatment to subjects who completed study hgs1006-c1056 in the united states, to evaluate the long-term safety and efficacy of belimumab(lymphostat-b™) in subjects with sle disease.

this is a long-term continuation study to provide continuing treatment to subjects who completed study hgs1006-c1056 in the united states. this study is to evaluate the long-term safety and efficacy of belimumab (lymphostat-b™) in subjects with sle disease.

Eligibility criteria:
inclusion criteria: * have completed the hgs1006-c1056 protocol in the united states through week 72 visit. * be able to receive 1st dose of belimumab for hgs 1006-c1066 four weeks after last dose in hgs1006-c1056. exclusion criteria: * have developed any other medical disease or condition that has made the subject unsuitable for this study in the opinion of their physician.

Keywords: systemic lupus erythematosus belimumab sle antibodies lupus autoimmune diseases
magnesium in liver cirrhosis

Conditions: LIVER CIRRHOSIS

Summary: several studies have shown in patients magnesium deficiency with liver cirrhosis. patients with liver cirrhosis showed considerably reduced muscle strength and muscle magnesium. we suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.

magnesium is the fourth most abundant cation in the body and plays an important physiological role in many of its functions. there are no readily available and easy methods to assess magnesium status but it is estimated that magnesium deficiency is a common problem. magnesium deficiency can cause a wide variety of features including hypocalcaemia, hypokalaemia and cardiac and neurological manifestations. chronic low magnesium state has been associated with a number of chronic diseases including diabetes, hypertension, coronary heart disease, and osteoporosis. there are not enough studies on magnesium status in chronic cirrhotics who may be in depletion. however , several studies have shown in patients magnesium deficiency with liver cirrhosis. patients with liver cirrhosis showed considerably reduced muscle strength and muscle mg . magnesium may have a role in the neuromuscular and neuropsychiatric manifestations of chronic liver disease (hepatic encephalopathy and muscle cramps). the use of magnesium as a therapeutic agent in asthma, myocardial infarction, and pre-eclampsia is also discussed. we suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.

Eligibility criteria:
inclusion criteria: * patients with liver cirrhosis exclusion criteria: * pregnant women * patients with acute or chronic renal failure (cr\>1.5) * congestive heart failure nyha 3-4 * patient with active cancer * patients with dementia or mental retardation

Keywords: liver cirrhosis magnesium minimal encephalopathy muscle weakness
safety/efficacy of nepafenac punctal plug delivery system compared to placebo to control ocular pain/inflammation after cataract

Conditions: Pain; Inflammation

Summary: this is a phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. one (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two treatment groups: n-ppds or p-ppds, which are inserted in the lower punctum of the subject's scheduled surgical eye. all plugs will remain in the study subject's lower punctum for a period of 2 weeks following cataract surgery.

this is a phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. one (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two treatment groups: group a: a total of 50 study subjects (50 eyes) will have an n-ppds inserted in the lower punctum of their scheduled surgical eye. group b: a total of 25 study subjects (25 eyes) will have a p-ppds inserted in the lower punctum of their scheduled surgical eye. all plugs will remain in the study subject's lower punctum for a period of 2 weeks following cataract surgery.

Eligibility criteria:
inclusion criteria: 1. a male or female subject in good general health, ≥ 22 years of age at the time of the screening visit 2. a subject with a cataract for which routine phacoemulsification extraction and implantation of an intraocular lens has been planned 3. a subject has a lower puncta that can be dilated to 1.0 mm in their scheduled surgical eye exclusion criteria: 1. a subject with a history of complications, adverse events, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in either eye 2. a subject with structural lid abnormalities (e.g., ectropion, entropion) in their schedule surgical eye 3. a subject with a puncta \>0.9 mm prior to dilation in their scheduled surgical eye 4. a subject with any signs of intraocular inflammation (cells/flare) in either eye at the screening visit 5. a subject with a known sensitivity to nepafenac or any inactive ingredient of the punctum plug, silicone, fluorescein, topical anesthetic, or any other products required for study procedures or cataract surgery 6. a subject with a history of chronic/recurrent inflammatory eye disease (e.g., scleritis, uveitis, herpes keratitis) in either eye

Keywords: treatment of pain and inflammation after cataract surgery
cto registry from insight of ivus in fuwai hospital

Conditions: Coronary Heart Disease; Chronic Total Occlusion of Coronary Artery; Percutaneous Coronary Intervention; Intravascular Ultrasound

Summary: to evaluate the long-term outcome of chronic total occlusion (cto) patients underwent contemporary percutaneous coronary intervention (pci) techniques, we design this single-center, large-sample, prospective registry with five-year clinical follow-up, based on the intravascular ultrasound (ivus) finding.

the study plan to include the patients with a cto lesion in one of the three main epicardial coronary artery (diameter more than 2.5 mm) as the only target lesion. the cto lesion is defined as 0 grade of thrombolysis in myocardial infarction (timi) flow with evidence of occlusion duration more than 3 months. all the pci procedure will be performed by a group of certified operators in fuwai hospital, beijing, china. all patients evaluate ivus with automatic pullback (opticross, boston scientific, us) performed after wire crossing. all the included patients are planned for five-year follow-up.

Eligibility criteria:
inclusion criteria: * male or female patient \>18 years old * thrombolysis in myocardial infarction trial (timi) 0 grade. * evidence of occlusion period more than 3 months. * patients eligible for pci. * patients eligible for coronary artery bypass graft (cabg). * target vessel is one of the three main epicardial coronary arteries. exclusion criteria: * acute myocardial infarction with ongoing st-elevation * target vessel is left main or graft vessel. * target vessel diameter \< 2.5 mm. * other situations ineligible for pci judged in clinical practice. * left ventricular ejection fraction \<30%